Lymphangiogenesis and metastasis-A closer look at the neuropilin/semaphorin3 axis

Microvascular Research

Volumn 96, Issue , 2014, Pages 68-76

  Migliozzi, Matthew T ^a   Mucka, Patrick ^a   Bielenberg, Diane R ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Cancer; Lymphangiogenesis; Metastasis; Neuropilin; Semaphorin

Indexed keywords

ANGIOPOIETIN 2; CCL1 CHEMOKINE; CHEMOKINE RECEPTOR CCR8; INTEGRIN LINKED KINASE; MITOGEN ACTIVATED PROTEIN KINASE; NEUROPILIN; NEUROPILIN 1; NEUROPILIN 2; PLACENTAL GROWTH FACTOR; PROTEIN KINASE B; SCATTER FACTOR; SEMAPHORIN; SEMAPHORIN 3A; SEMAPHORIN 3B; SEMAPHORIN 3C; SEMAPHORIN 3E; SEMAPHORIN 3F; SEMAPHORIN 3G; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PROX1; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN E; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; SEMA3A PROTEIN, MOUSE;

AMINO TERMINAL SEQUENCE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; COMPLEX FORMATION; CONGENITAL LYMPHATIC SYSTEM DISORDER; EMBRYO PATTERN FORMATION; ENDOTHELIUM CELL; GENE; GENE CONTROL; GENE FUNCTION; GENE IDENTIFICATION; GENE INTERACTION; GENE LOCUS; GREAT VESSELS TRANSPOSITION; HUMAN; LIGAND BINDING; LYMPH NODE METASTASIS; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; MELANOMA; NONHUMAN; NRP GENE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REGULATOR GENE; REVIEW; SEMA3 GENE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; VEGF GENE; ANIMAL; BAGG ALBINO MOUSE; LYMPH VESSEL; LYMPHATIC SYSTEM; METASTASIS; MOUSE; MUTATION; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE; VASCULARIZATION;

ANIMALS; HUMANS; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; LYMPHATIC SYSTEM; LYMPHATIC VESSELS; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MUTATION; NEOPLASM METASTASIS; NEOPLASMS; NEUROPILINS; SEMAPHORIN-3A; SIGNAL TRANSDUCTION;

EID: 84920489515     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2014.07.006     Document Type: Review

References (112)

1. Acevedo L.M., Barillas S., Weis S.M., Göthert J.R., Cheresh D.A. Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. Blood 2008, 111:2674-2680. 10.1182/blood-2007-08-110205.
2. Adams R.H., Lohrum M., Klostermann A., Betz H., Püschel A.W. The chemorepulsive activity of secreted semaphorins is regulated by furin-dependent proteolytic processing. EMBO J. 1997, 16:6077-6086. 10.1093/emboj/16.20.6077.
3. Alexander J.S., Ganta V.C., Jordan P.A., Witte M.H. Gastrointestinal lymphatics in health and disease. Pathophysiology 2010, 17:315-335. 10.1016/j.pathophys.2009.09.003.
4. Alitalo A., Detmar M. Interaction of tumor cells and lymphatic vessels in cancer progression. Oncogene 2012, 31:4499-4508. 10.1038/onc.2011.602.
5. Appleton B.A., Wu P., Maloney J., Yin J., Liang W.-C., Stawicki S., Mortara K., Bowman K.K., Elliott J.M., Desmarais W., Bazan J.F., Bagri A., Tessier-Lavigne M., Koch A.W., Wu Y., Watts R.J., Wiesmann C. Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding. EMBO J. 2007, 26:4902-4912. 10.1038/sj.emboj.7601906.
6. Baluk P., Fuxe J., Hashizume H., Romano T., Lashnits E., Butz S., Vestweber D., Corada M., Molendini C., Dejana E., McDonald D.M. Functionally specialized junctions between endothelial cells of lymphatic vessels. J. Exp. Med. 2007, 204:2349-2362. 10.1084/jem.20062596.
7. Banerji S., Ni J., Wang S.X., Clasper S., Su J., Tammi R., Jones M., Jackson D.G. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J. Cell Biol. 1999, 144:789-801.
8. Banyard J., Chung I., Migliozzi M., Phan D.T., Wilson A.M., Zetter B.R., Bielenberg D.R. Identification of genes regulating migration and invasion using a new model of metastatic prostate cancer. BMC Cancer 2014, 14:387. 10.1186/1471-2407-14-387.
9. Beck B., Driessens G., Goossens S., Youssef K.K., Kuchnio A., Caauwe A., Sotiropoulou P.A., Loges S., Lapouge G., Candi A., Mascre G., Drogat B., Dekoninck S., Haigh J.J., Carmeliet P., Blanpain C. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 2011, 478:399-403. 10.1038/nature10525.
10. Behar O., Golden J.A., Mashimo H., Schoen F.J., Fishman M.C. Semaphorin III is needed for normal patterning and growth of nerves, bones and heart. Nature 1996, 383:525-528. 10.1038/383525a0.
11. Bellini C., Rutigliani M., Boccardo F., Campisi C., Bellini T., Bonioli E., Fulcheri E. Are there lymphatic vessels in the placenta?. Lymphology 2012, 45:34-36.
12. Bergé M., Allanic D., Bonnin P., de Montrion C., Richard J., Suc M., Boivin J.-F., Contrerès J.-O., Lockhart B.P., Pocard M., Lévy B.I., Tucker G.C., Tobelem G., Merkulova-Rainon T. Neuropilin-1 is upregulated in hepatocellular carcinoma and contributes to tumour growth and vascular remodelling. J. Hepatol. 2011, 55:866-875. 10.1016/j.jhep.2011.01.033.
13. Bielenberg D.R., Klagsbrun M. Targeting endothelial and tumor cells with semaphorins. Cancer Metastasis Rev. 2007, 26:421-431. 10.1007/s10555-007-9097-4.
14. Bielenberg D.R., Hida Y., Shimizu A., Kaipainen A., Kreuter M., Kim C.C., Klagsbrun M. Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J. Clin. Invest. 2004, 114:1260-1271. 10.1172/JCI21378.
15. Bielenberg D.R., Pettaway C.A., Takashima S., Klagsbrun M. Neuropilins in neoplasms: expression, regulation, and function. Exp. Cell Res. 2006, 312:584-593. 10.1016/j.yexcr.2005.11.024.
16. Bielenberg D.R., Seth A., Shimizu A., Pelton K., Cristofaro V., Ramachandran A., Zwaans B.M.M., Chen C., Krishnan R., Seth M., Huang L., Takashima S., Klagsbrun M., Sullivan M.P., Adam R.M. Increased smooth muscle contractility in mice deficient for neuropilin 2. Am. J. Pathol. 2012, 181:548-559. 10.1016/j.ajpath.2012.04.013.
17. Bouvrée K., Brunet I., Del Toro R., Gordon E., Prahst C., Cristofaro B., Mathivet T., Xu Y., Soueid J., Fortuna V., Miura N., Aigrot M.-S., Maden C.H., Ruhrberg C., Thomas J.L., Eichmann A. Semaphorin3A, neuropilin-1, and plexinA1 are required for lymphatic valve formation. Circ. Res. 2012, 111:437-445. 10.1161/CIRCRESAHA.112.269316.
18. Breiteneder-Geleff S., Soleiman A., Kowalski H., Horvat R., Amann G., Kriehuber E., Diem K., Weninger W., Tschachler E., Alitalo K., Kerjaschki D. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am. J. Pathol. 1999, 154:385-394. 10.1016/S0002-9440(10)65285-6.
19. Cai H., Reed R.R. Cloning and characterization of neuropilin-1-interacting protein: a PSD-95/Dlg/ZO-1 domain-containing protein that interacts with the cytoplasmic domain of neuropilin-1. J. Neurosci. 1999, 19:6519-6527.
20. Cao R., Björndahl M.A., Gallego M.I., Chen S., Religa P., Hansen A.J., Cao Y. Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action. Blood 2006, 107:3531-3536. 10.1182/blood-2005-06-2538.
21. Cassinelli G., Zuco V., Gatti L., Lanzi C., Zaffaroni N., Colombo D., Perego P. Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells. Curr. Med. Chem. 2013, 20:1923-1945.
22. Caunt M., Mak J., Liang W.-C., Stawicki S., Pan Q., Tong R.K., Kowalski J., Ho C., Reslan H.B., Ross J., Berry L., Kasman I., Zlot C., Cheng Z., Le Couter J., Filvaroff E.H., Plowman G., Peale F., French D., Carano R., Koch A.W., Wu Y., Watts R.J., Tessier-Lavigne M., Bagri A. Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 2008, 13:331-342. 10.1016/j.ccr.2008.01.029.
23. Cerani A., Tetreault N., Menard C., Lapalme E., Patel C., Sitaras N., Beaudoin F., Leboeuf D., De Guire V., Binet F., Dejda A., Rezende F.A., Miloudi K., Sapieha P. Neuron-derived semaphorin 3A is an early inducer of vascular permeability in diabetic retinopathy via neuropilin-1. Cell Metab. 2013, 18:505-518. 10.1016/j.cmet.2013.09.003.
24. Coso S., Zeng Y., Opeskin K., Williams E.D. Vascular endothelial growth factor receptor-3 directly interacts with phosphatidylinositol 3-kinase to regulate lymphangiogenesis. PLoS ONE 2012, 7:e39558. 10.1371/journal.pone.0039558.
25. Dadras S.S., Lange-Asschenfeldt B., Velasco P., Nguyen L., Vora A., Muzikansky A., Jahnke K., Hauschild A., Hirakawa S., Mihm M.C., Detmar M. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod. Pathol. 2005, 18:1232-1242. 10.1038/modpathol.3800410.
26. Das S., Sarrou E., Podgrabinska S., Cassella M., Mungamuri S.K., Feirt N., Gordon R., Nagi C.S., Wang Y., Entenberg D., Condeelis J., Skobe M. Tumor cell entry into the lymph node is controlled by CCL1 chemokine expressed by lymph node lymphatic sinuses. J. Exp. Med. 2013, 210:1509-1528. 10.1084/jem.20111627.
27. Dickinson A.J., Gausas R.E. Orbital lymphatics: do they exist?. Eye (Lond) 2006, 20:1145-1148. 10.1038/sj.eye.6702378.
28. Doeden K., Ma Z., Narasimhan B., Swetter S.M., Detmar M., Dadras S.S. Lymphatic invasion in cutaneous melanoma is associated with sentinel lymph node metastasis. J. Cutan. Pathol. 2009, 36:772-780. 10.1111/j.1600-0560.2008.01166.x.
29. Enquist I.B., Good Z., Jubb A.M., Fuh G., Wang X., Junttila M.R., Jackson E.L., Leong K.G. Lymph node-independent liver metastasis in a model of metastatic colorectal cancer. Nat. Commun. 2014, 5:3530. 10.1038/ncomms4530.
30. Fantin A., Schwarz Q., Davidson K., Normando E.M., Denti L., Ruhrberg C. The cytoplasmic domain of neuropilin 1 is dispensable for angiogenesis, but promotes the spatial separation of retinal arteries and veins. Development 2011, 138:4185-4191. 10.1242/dev.070037.
31. Fantin A., Herzog B., Mahmoud M., Yamaji M., Plein A., Denti L., Ruhrberg C., Zachary I. Neuropilin 1 (NRP1) hypomorphism combined with defective VEGF-A binding reveals novel roles for NRP1 in developmental and pathological angiogenesis. Development 2014, 141:556-562. 10.1242/dev.103028.
32. Favier B., Alam A., Barron P., Bonnin J., Laboudie P., Fons P., Mandron M., Herault J.-P., Neufeld G., Savi P., Herbert J.-M., Bono F. Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood 2006, 108:1243-1250. 10.1182/blood-2005-11-4447.
33. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat. Rev. Drug Discov. 2007, 6:273-286. 10.1038/nrd2115.
34. Friedl P., Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat. Rev. Cancer 2003, 3:362-374. 10.1038/nrc1075.
35. Gagnon M.L., Bielenberg D.R., Gechtman Z., Miao H.Q., Takashima S., Soker S., Klagsbrun M. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: in vivo expression and antitumor activity. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:2573-2578. 10.1073/pnas.040337597.
36. Gaur P., Bielenberg D.R., Samuel S., Bose D., Zhou Y., Gray M.J., Dallas N.A., Fan F., Xia L., Lu J., Ellis L.M. Role of class 3 semaphorins and their receptors in tumor growth and angiogenesis. Clin. Cancer Res. 2009, 15:6763-6770. 10.1158/1078-0432.CCR-09-1810.
37. Geretti E., Shimizu A., Kurschat P., Klagsbrun M. Site-directed mutagenesis in the B-neuropilin-2 domain selectively enhances its affinity to VEGF165, but not to semaphorin 3F. J. Biol. Chem. 2007, 282:25698-25707. 10.1074/jbc.M702942200.
38. Gherardi E., Love C.A., Esnouf R.M., Jones E.Y. The sema domain. Curr. Opin. Struct. Biol. 2004, 14:669-678. 10.1016/j.sbi.2004.10.010.
39. Giger R.J., Urquhart E.R., Gillespie S.K., Levengood D.V., Ginty D.D., Kolodkin A.L. Neuropilin-2 is a receptor for semaphorin IV: insight into the structural basis of receptor function and specificity. Neuron 1998, 21:1079-1092.
40. Goel H.L., Bae D., Pursell B., Gouvin L.M., Lu S., Mercurio A.M. Neuropilin-2 promotes branching morphogenesis in the mouse mammary gland. Development 2011, 138:2969-2976. 10.1242/dev.051318.
41. Gu C., Rodriguez E.R., Reimert D.V., Shu T., Fritzsch B., Richards L.J., Kolodkin A.L., Ginty D.D. Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development. Dev. Cell 2003, 5:45-57.
42. Gu C., Yoshida Y., Livet J., Reimert D.V., Mann F., Merte J., Henderson C.E., Jessell T.M., Kolodkin A.L., Ginty D.D. Semaphorin 3E and plexin-D1 control vascular pattern independently of neuropilins. Science 2005, 307:265-268.
43. Hägerling R., Pollmann C., Andreas M., Schmidt C., Nurmi H., Adams R.H., Alitalo K., Andresen V., Schulte-Merker S., Kiefer F. A novel multistep mechanism for initial lymphangiogenesis in mouse embryos based on ultramicroscopy. EMBO J. 2013, 32:629-644. 10.1038/emboj.2012.340.
44. Herzog Y., Kalcheim C., Kahane N., Reshef R., Neufeld G. Differential expression of neuropilin-1 and neuropilin-2 in arteries and veins. Mech. Dev. 2001, 109:115-119.
45. Jain R.K., Munn L.L., Fukumura D. Lymphangiography of the mouse ear. Cold Spring Harb. Protoc. 2012, 1179-1180. 10.1101/pdb.prot072116.
46. Joza S., Wang J., Tseu I., Ackerley C., Post M. Fetal, but not postnatal, deletion of semaphorin-neuropilin-1 signaling affects murine alveolar development. Am. J. Respir. Cell Mol. Biol. 2013, 49:627-636. 10.1165/rcmb.2012-0407OC.
47. Jurisic G., Maby-El Hajjami H., Karaman S., Ochsenbein A.M., Alitalo A., Siddiqui S.S., Ochoa Pereira C., Petrova T.V., Detmar M. An unexpected role of semaphorin3a-neuropilin-1 signaling in lymphatic vessel maturation and valve formation. Circ. Res. 2012, 111:426-436. 10.1161/CIRCRESAHA.112.269399.
48. Kaipainen A., Bielenberg D.R. Chapter 125: hemangiogenesis versus lymphangiogenesis. Encyclopedia of the Eye 2010, vol. 2:227-232. Elsevier Ltd., Oxford.
49. Kaipainen A., Bielenberg D.R. Hemangiogenesis versus lymphangiogenesis in part II. Angiogenesis in the eye and its dysfunction in the retina, cornea, and vitreous. Immunology, Inflammation, and Diseases of the Eye 2011, 257-262. Academic Press (Elsevier Ltd), Oxford. Dart, Dana, D'Amore, Niederkorn (Eds.).
50. Kaipainen A., Korhonen J., Mustonen T., van Hinsbergh V.W., Fang G.H., Dumont D., Breitman M., Alitalo K. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:3566-3570.
51. Kajiya K., Hirakawa S., Ma B., Drinnenberg I., Detmar M. Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J. 2005, 24:2885-2895. 10.1038/sj.emboj.7600763.
52. Karaman S., Detmar M. Mechanisms of lymphatic metastasis. J. Clin. Invest. 2014, 124:922-928. 10.1172/JCI71606.
53. Karkkainen M.J., Saaristo A., Jussila L., Karila K.A., Lawrence E.C., Pajusola K., Bueler H., Eichmann A., Kauppinen R., Kettunen M.I., Yla-Herttuala S., Finegold D.N., Ferrell R.E., Alitalo K. A model for gene therapy of human hereditary lymphedema. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:12677-12682. 10.1073/pnas.221449198.
54. Karkkainen M.J., Haiko P., Sainio K., Partanen J., Taipale J., Petrova T.V., Jeltsch M., Jackson D.G., Talikka M., Rauvala H., Betsholtz C., Alitalo K. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat. Immunol. 2004, 5:74-80. 10.1038/ni1013.
55. Kawasaki T., Kitsukawa T., Bekku Y., Matsuda Y., Sanbo M., Yagi T., Fujisawa H. A requirement for neuropilin-1 in embryonic vessel formation. Development 1999, 126:4895-4902.
56. Kessler O., Shraga-Heled N., Lange T., Gutmann-Raviv N., Sabo E., Baruch L., Machluf M., Neufeld G. Semaphorin-3F is an inhibitor of tumor angiogenesis. Cancer Res. 2004, 64:1008-1015.
57. Kigel B., Varshavsky A., Kessler O., Neufeld G. Successful inhibition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells. PLoS ONE 2008, 3:e3287. 10.1371/journal.pone.0003287.
58. Kitsukawa T., Shimono A., Kawakami A., Kondoh H., Fujisawa H. Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs. Development 1995, 121:4309-4318.
59. Kitsukawa T., Shimizu M., Sanbo M., Hirata T., Taniguchi M., Bekku Y., Yagi T., Fujisawa H. Neuropilin-semaphorin III/D-mediated chemorepulsive signals play a crucial role in peripheral nerve projection in mice. Neuron 1997, 19:995-1005.
60. Klagsbrun M., Eichmann A. A role for axon guidance receptors and ligands in blood vessel development and tumor angiogenesis. Cytokine Growth Factor Rev. 2005, 16:535-548. 10.1016/j.cytogfr.2005.05.002.
61. Klagsbrun M., Takashima S., Mamluk R. The role of neuropilin in vascular and tumor biology. Adv. Exp. Med. Biol. 2002, 515:33-48.
62. Klostermann A., Lohrum M., Adams R.H., Püschel A.W. The chemorepulsive activity of the axonal guidance signal semaphorin D requires dimerization. J. Biol. Chem. 1998, 273:7326-7331.
63. Koch S., van Meeteren L.A., Morin E., Testini C., Weström S., Björkelund H., Le Jan S., Adler J., Berger P., Claesson-Welsh L. NRP1 presented in trans to the endothelium arrests VEGFR2 endocytosis, preventing angiogenic signaling and tumor initiation. Dev. Cell 2014, 28:633-646. 10.1016/j.devcel.2014.02.010.
64. Kolodkin A.L., Levengood D.V., Rowe E.G., Tai Y.T., Giger R.J., Ginty D.D. Neuropilin is a semaphorin III receptor. Cell 1997, 90:753-762.
65. Kusy S., Potiron V., Zeng C., Franklin W., Brambilla E., Minna J., Drabkin H.A., Roche J. Promoter characterization of semaphorin SEMA3F, a tumor suppressor gene. Biochim. Biophys. Acta 2005, 1730:66-76. 10.1016/j.bbaexp.2005.05.008.
66. Kutschera S., Weber H., Weick A., De Smet F., Genove G., Takemoto M., Prahst C., Riedel M., Mikelis C., Baulande S., Champseix C., Kummerer P., Conseiller E., Multon M.-C., Héroult M., Bicknell R., Carmeliet P., Betsholtz C., Augustin H.G. Differential endothelial transcriptomics identifies semaphorin 3G as a vascular class 3 semaphorin. Arterioscler. Thromb. Vasc. Biol. 2011, 31:151-159. 10.1161/ATVBAHA.110.215871.
67. Lanahan A., Zhang X., Fantin A., Zhuang Z., Rivera-Molina F., Speichinger K., Prahst C., Zhang J., Wang Y., Davis G., Toomre D., Ruhrberg C., Simons M. The neuropilin 1 cytoplasmic domain is required for VEGF-A-dependent arteriogenesis. Dev. Cell 2013, 25:156-168. 10.1016/j.devcel.2013.03.019.
68. Le A., Zielinski R., He C., Crow M.T., Biswal S., Tuder R.M., Becker P.M. Pulmonary epithelial neuropilin-1 deletion enhances development of cigarette smoke-induced emphysema. Am. J. Respir. Crit. Care Med. 2009, 180:396-406. 10.1164/rccm.200809-1483OC.
69. Leak L.V., Burke J.F. Ultrastructural studies on the lymphatic anchoring filaments. J. Cell Biol. 1968, 36:129-149.
70. Lloyd A.C. Distinct functions for ERKs?. J. Biol. 2006, 5:13. 10.1186/jbiol46.
71. Mäkinen T., Jussila L., Veikkola T., Karpanen T., Kettunen M.I., Pulkkanen K.J., Kauppinen R., Jackson D.G., Kubo H., Nishikawa S., Yla-Herttuala S., Alitalo K. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat. Med. 2001, 7:199-205. 10.1038/84651.
72. Mamluk R., Gechtman Z., Kutcher M.E., Gasiunas N., Gallagher J., Klagsbrun M. Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain. J. Biol. Chem. 2002, 277:24818-24825. 10.1074/jbc.M200730200.
73. Mamluk R., Detmar M., Klagsbrun M., Bielenberg D. Soluble neuropilin targeted to the skin inhibits vascular permeability. Angiogenesis 2005, 8:217-227. 10.1007/s10456-005-9009-6.
74. Neufeld G., Kessler O. The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nat. Rev. Cancer 2008, 8:632-645. 10.1038/nrc2404.
75. Oliver G., Detmar M. The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature. Genes Dev. 2002, 16:773-783. 10.1101/gad.975002.
76. Pan Q., Chanthery Y., Liang W.-C., Stawicki S., Mak J., Rathore N., Tong R.K., Kowalski J., Yee S.F., Pacheco G., Ross S., Cheng Z., Le Couter J., Plowman G., Peale F., Koch A.W., Wu Y., Bagri A., Tessier-Lavigne M., Watts R.J. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 2007, 11:53-67. 10.1016/j.ccr.2006.10.018.
77. Panigrahy D., Adini I., Mamluk R., Levonyak N., Bruns C., D'Amore P.A., Klagsbrun M., Bielenberg D.R. Regulation of soluble neuropilin 1, an endogenous angiogenesis inhibitor, in liver development and regeneration. Pathology 2014, 46:416-423. 10.1097/PAT.0000000000000121.
78. Paye J.M.D., Phng L.-K., Lanahan A.A., Gerhard H., Simons M. Synectin-dependent regulation of arterial maturation. Dev. Dyn. 2009, 238:604-610. 10.1002/dvdy.21880.
79. Perälä N., Sariola H., Immonen T. More than nervous: the emerging roles of plexins. Differentiation 2012, 83:77-91. 10.1016/j.diff.2011.08.001.
80. Poggi P., Marchetti C., Calligaro A., Casasco A., Scelsi R. Lymphatic vessels in the developing diaphragm of the rat. Acta Anat. (Basel) 1991, 142:111-117.
81. Potiron V.A., Sharma G., Nasarre P., Clarhaut J.A., Augustin H.G., Gemmill R.M., Roche J., Drabkin H.A. Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells. Cancer Res. 2007, 67:8708-8715. 10.1158/0008-5472.CAN-06-3612.
82. Prahst C., Héroult M., Lanahan A.A., Uziel N., Kessler O., Shraga-Heled N., Simons M., Neufeld G., Augustin H.G. Neuropilin-1-VEGFR-2 complexing requires the PDZ-binding domain of neuropilin-1. J. Biol. Chem. 2008, 283:25110-25114. 10.1074/jbc.C800137200.
83. Qu X., Tompkins K., Batts L.E., Puri M., Baldwin H.S., Baldwin S. Abnormal embryonic lymphatic vessel development in Tie1 hypomorphic mice. Development 2010, 137:1285-1295. 10.1242/dev.043380.
84. Riese A., Eilert Y., Meyer Y., Arin M., Baron J.M., Eming S., Krieg T., Kurschat P. Epidermal expression of neuropilin 1 protects murine keratinocytes from UVB-induced apoptosis. PLoS ONE 2012, 7:e50944. 10.1371/journal.pone.0050944.
85. Romi E., Gokhman I., Wong E., Antonovsky N., Ludwig A., Sagi I., Saftig P., Tessier-Lavigne M., Yaron A. ADAM metalloproteases promote a developmental switch in responsiveness to the axonal repellant Sema3A. Nat. Commun. 2014, 5:4058. 10.1038/ncomms5058.
86. Rossignol M., Beggs A.H., Pierce E.A., Klagsbrun M. Human neuropilin-1 and neuropilin-2 map to 10p12 and 2q34, respectively. Genomics 1999, 57:459-460. 10.1006/geno.1999.5790.
87. Sabin F. On the Origin of the Lymphatic System from the Veins and the Development of the Lymph Hearts and Thoracic Duct in the Pig 1902, 1:367-391.
88. Salikhova A., Wang L., Lanahan A.A., Liu M., Simons M., Leenders W.P.J., Mukhopadhyay D., Horowitz A. Vascular endothelial growth factor and semaphorin induce neuropilin-1 endocytosis via separate pathways. Circ. Res. 2008, 103:e71-e79. 10.1161/CIRCRESAHA.108.183327.
89. Sauter B., Foedinger D., Sterniczky B., Wolff K., Rappersberger K. Immunoelectron microscopic characterization of human dermal lymphatic microvascular endothelial cells. Differential expression of CD31, CD34, and type IV collagen with lymphatic endothelial cells vs blood capillary endothelial cells in normal human skin, lymphangioma, and hemangioma in situ. J. Histochem. Cytochem. 1998, 46:165-176.
90. Sekido Y., Bader S., Latif F., Chen J.Y., Duh F.M., Wei M.H., Albanesi J.P., Lee C.C., Lerman M.I., Minna J.D. Human semaphorins A(V) and IV reside in the 3p21.3 small cell lung cancer deletion region and demonstrate distinct expression patterns. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:4120-4125.
91. Shen J., Samul R., Zimmer J., Liu H., Liang X., Hackett S., Campochiaro P.A. Deficiency of neuropilin 2 suppresses VEGF-induced retinal neovascularization. Mol. Med. 2004, 10:12-18.
92. Shimizu A., Mammoto A., Italiano J.E., Pravda E., Dudley A.C., Ingber D.E., Klagsbrun M. ABL2/ARG tyrosine kinase mediates SEMA3F-induced RhoA inactivation and cytoskeleton collapse in human glioma cells. J. Biol. Chem. 2008, 283:27230-27238. 10.1074/jbc.M804520200.
93. Singh N., Tiem M., Watkins R., Cho Y.K., Wang Y., Olsen T., Uehara H., Mamalis C., Luo L., Oakey Z., Ambati B.K. Soluble vascular endothelial growth factor receptor 3 is essential for corneal alymphaticity. Blood 2013, 121:4242-4249. 10.1182/blood-2012-08-453043.
94. Skobe M., Hawighorst T., Jackson D.G., Prevo R., Janes L., Velasco P., Riccardi L., Alitalo K., Claffey K., Detmar M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 2001, 7:192-198. 10.1038/84643.
95. Snuderl M., Batista A., Kirkpatrick N.D., Ruiz de Almodovar C., Riedemann L., Walsh E.C., Anolik R., Huang Y., Martin J.D., Kamoun W., Knevels E., Schmidt T., Farrar C.T., Vakoc B.J., Mohan N., Chung E., Roberge S., Peterson T., Bais C., Zhelyazkova B.H., Yip S., Hasselblatt M., Rossig C., Niemeyer E., Ferrara N., Klagsbrun M., Duda D.G., Fukumura D., Xu L., Carmeliet P., Jain R.K. Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell 2013, 152:1065-1076. 10.1016/j.cell.2013.01.036.
96. Soker S., Takashima S., Miao H.Q., Neufeld G., Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998, 92:735-745.
97. Soker S., Miao H.-Q., Nomi M., Takashima S., Klagsbrun M. VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J. Cell. Biochem. 2002, 85:357-368.
98. Srinivasan R.S., Dillard M.E., Lagutin O.V., Lin F.-J., Tsai S., Tsai M.-J., Samokhvalov I.M., Oliver G. Lineage tracing demonstrates the venous origin of the mammalian lymphatic vasculature. Genes Dev. 2007, 21:2422-2432. 10.1101/gad.1588407.
99. Stanton A.W., Patel H.S., Levick J.R., Mortimer P.S. Increased dermal lymphatic density in the human leg compared with the forearm. Microvasc. Res. 1999, 57:320-328. 10.1006/mvre.1998.2141.
100. Sulpice E., Plouët J., Bergé M., Allanic D., Tobelem G., Merkulova-Rainon T. Neuropilin-1 and neuropilin-2 act as coreceptors, potentiating proangiogenic activity. Blood 2008, 111:2036-2045. 10.1182/blood-2007-04-084269.
101. Takashima S., Kitakaze M., Asakura M., Asanuma H., Sanada S., Tashiro F., Niwa H., Miyazaki Ji J., Hirota S., Kitamura Y., Kitsukawa T., Fujisawa H., Klagsbrun M., Hori M. Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:3657-3662. 10.1073/pnas.022017899.
102. Vander Kooi C.W., Jusino M.A., Perman B., Neau D.B., Bellamy H.D., Leahy D.J. Structural basis for ligand and heparin binding to neuropilin B domains. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:6152-6157.
103. Varshavsky A., Kessler O., Abramovitch S., Kigel B., Zaffryar S., Akiri G., Neufeld G. Semaphorin-3B is an angiogenesis inhibitor that is inactivated by furin-like pro-protein convertases. Cancer Res. 2008, 68:6922-6931. 10.1158/0008-5472.CAN-07-5408.
104. Von Andrian U.H., Mempel T.R. Homing and cellular traffic in lymph nodes. Nat. Rev. Immunol. 2003, 3:867-878. 10.1038/nri1222.
105. West D.C., Rees C.G., Duchesne L., Patey S.J., Terry C.J., Turnbull J.E., Delehedde M., Heegaard C.W., Allain F., Vanpouille C., Ron D., Fernig D.G. Interactions of multiple heparin binding growth factors with neuropilin-1 and potentiation of the activity of fibroblast growth factor-2. J. Biol. Chem. 2005, 280:13457-13464. 10.1074/jbc.M410924200.
106. Wigle J.T., Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell 1999, 98:769-778.
107. Xu Y., Yuan L., Mak J., Pardanaud L., Caunt M., Kasman I., Larrivée B., Del Toro R., Suchting S., Medvinsky A., Silva J., Yang J., Thomas J.-L., Koch A.W., Alitalo K., Eichmann A., Bagri A. Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. J. Cell Biol. 2010, 188:115-130. 10.1083/jcb.200903137.
108. Yang Y., Oliver G. Development of the mammalian lymphatic vasculature. J. Clin. Invest. 2014, 124:888-897. 10.1172/JCI71609.
109. Yaniv K., Isogai S., Castranova D., Dye L., Hitomi J., Weinstein B.M. Live imaging of lymphatic development in the zebrafish. Nat. Med. 2006, 12:711-716. 10.1038/nm1427.
110. Yao L.-C., Baluk P., Srinivasan R.S., Oliver G., McDonald D.M. Plasticity of button-like junctions in the endothelium of airway lymphatics in development and inflammation. Am. J. Pathol. 2012, 180:2561-2575. 10.1016/j.ajpath.2012.02.019.
111. Yuan L., Moyon D., Pardanaud L., Bréant C., Karkkainen M.J., Alitalo K., Eichmann A. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 2002, 129:4797-4806.
112. Zwaans B.M.M., Bielenberg D.R. Potential therapeutic strategies for lymphatic metastasis. Microvasc. Res. 2007, 74:145-158. 10.1016/j.mvr.2007.08.006.